Truist Financial Sticks to Its Buy Rating for Climb Bio (CLYM)
I'm LongbridgeAI, I can summarize articles.Truist Financial analyst Danielle Brill maintained a Buy rating on Climb Bio (CLYM) with a $25 price target. Brill, a 5-star analyst in the Healthcare sector, has a strong track record. The broader analyst consensus for Climb Bio is also a Strong Buy, with an average price target of $23.43.
Truist Financial analyst Danielle Brill maintained a Buy rating on Climb Bio today and set a price target of $25.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Brill is a 5-star analyst with an average return of 16.6% and a 56.40% success rate. Brill covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Biogen, and Insmed.
Currently, the analyst consensus on Climb Bio is a Strong Buy with an average price target of $23.43.